Bio-Thera Follows Hikma Deal With Sandoz Bevacizumab Alliance
Hikma Ustekinumab Deal Signed In Late August; Sandoz Oncology Pipeline Boosted
Sandoz has plugged another gap in its off-patent oncology pipeline, from which the company has rolled-out four marketed oncology biosimilars, by bringing in Bio-Thera Solutions’ BAT1706 proposed biosimilar to Avastin, including in the US and Europe.
You may also be interested in...
Bio-Thera has received US Food and Drug Administration approval for its bevacizumab biosimilar, marking the second biosimilar drug researched, developed and manufactured by a Chinese pharmaceutical company to receive US approval.
China’s Bio-Thera Solutions has revealed the details of its latest clinical trials for proposed biosimilar rivals to Cosentyx (secukinumab) and Nucala (mepolizumab).
The European Medicines Agency has accepted Biogen’s marketing authorization submission for its BIIB800, developed by Chinese firm Bio-Thera.